Anxiety and depression test

Key Takeaways

An anxiety and depression test is a validated screening questionnaire that helps clinicians systematically assess mental health symptoms using standardized scoring.

The PHQ-9, GAD-7, K10, HADS, and DASS-21 are evidence-based tools; all are administered in 5-15 minutes and produce quantifiable scores.

Screening tools identify symptoms, not diagnoses – only licensed mental health professionals can provide a clinical diagnosis following assessment.

Pabau’s digital forms feature allows practices to administer, score, and store anxiety and depression tests securely within a compliant clinical workflow.

Download your free anxiety and depression test

A depression and anxiety screening test gives you a fast, standardized read on symptom severity before you shape a treatment plan. This guide compares the five validated instruments clinicians rely on – the PHQ-9, GAD-7, K10, HADS, and DASS-21 – and shows how to score, document, and store each one.

Practice management software like Pabau lets you administer a depression test as a digital form, score it automatically, and file the result straight to the patient record, so screening adds clinical insight instead of paperwork.

What is an anxiety and depression test?

An anxiety and depression test is a validated clinical screening questionnaire that helps mental health professionals systematically assess symptoms of anxiety disorders and depressive conditions. These instruments use standardized questions and rating scales to quantify symptom severity and track changes over time.

Unlike self-diagnosis or informal assessment, validated screening tools are grounded in peer-reviewed psychometric research. They provide reliable baseline measurements and support informed clinical decision-making.

The most widely used instruments – PHQ-9 for depression and GAD-7 for anxiety – are publicly available, cost-free, and can be administered in under 10 minutes. Most instruments ask patients to rate each symptom over the past two weeks, which keeps a depression test anchored to current functioning rather than lifetime history.

A critical distinction: screening tools identify symptoms, not diagnoses. Only a licensed mental health professional can combine test results with clinical interview, medical history, and observed presentation to reach a formal diagnosis. As Mental Health America clarifies, “A screening is not a diagnosis.” The anxiety and depression test serves as a clinical aid, not a standalone diagnostic instrument.

How to use an anxiety and depression test in clinical practice

Each validated tool already specifies the depression questions to ask patients, so mental health practitioners administer a set list and fold it into five key workflow steps:

1. Administer at intake – Present the questionnaire during initial assessment or at session start to establish baseline symptom severity. Most patients complete it independently on paper or digital form in the waiting room or via patient compliance workflows.
2. Score immediately – Calculate the total score using published cutoff thresholds (e.g., PHQ-9: 10+ indicates moderate depression). Hand scoring takes 2-3 minutes; automated mental health EMR platforms can calculate scores in real time.
3. Document results – Record the test name, date, score, and any clinician notes in the patient’s clinical record. Digital mental health intake forms auto-populate records and timestamps.
4. Use in treatment planning – Inform diagnosis, treatment modality selection, and safety assessment. A PHQ-9 score above 20 signals severe depression and warrants immediate safety evaluation, including suicidal ideation screening. When body image concerns intersect with mood symptoms, a body neutrality worksheet can support ongoing treatment.
5. Track longitudinally – Readminister at regular intervals (e.g., every 4 weeks) to measure treatment response and adjust interventions. Graphing score trends over sessions provides objective evidence of progress.

For psychiatric evaluation templates, screening test administration is typically part of a broader intake battery. Many practices embed anxiety and depression screening into comprehensive mental health assessment workflows alongside risk assessment, substance use screening, and medical history review.

Comparing validated screening instruments

Five validated tools dominate mental health screening. Each differs in length, scoring scale, and clinical application.

PHQ-9 and GAD-7 are public domain – Pfizer released them royalty-free for clinical and research use, so no licensing fees or reproduction restrictions apply. The K10 is also free to use through its developer, Kessler, provided the source is credited. The DASS-21 is distributed free by the UNSW DASS research group.

The HADS works differently. It’s a copyrighted instrument (© Snaith & Zigmond), administered by GL Assessment or the Mapi Research Trust, and practices need a license – often for a fee – before reproducing or administering it.

The Hospital Anxiety and Depression Scale (HADS) and the depression anxiety and stress test (DASS-21) both split their results into separate subscales, which helps when you want anxiety and depression scored side by side. The PHQ-9 depression test stays narrower, giving you one clear depression score to track from session to session.

Other instruments, like the Beck Depression Inventory (BDI), are copyrighted and require licensing to reproduce – a cost barrier for some small practices. Trait-based tools such as the Big Five personality test serve a different purpose: they measure stable personality traits rather than current symptom severity, so they complement rather than replace a depression or anxiety screen.

Relevant CPT and HCPCS billing codes

Administering and scoring an anxiety and depression test is billable separately from the office visit, using codes for brief standardized assessments. Coverage and reimbursement vary by payer, so confirm current rules with your billing team before submitting claims.

Understanding anxiety and depression test scores

Each depression scale sets its own scoring range and interpretation thresholds, so a raw depression score only carries meaning once you map it to the right cutoffs. Clinicians need to know when a score warrants escalation or safety intervention.

PHQ-9 scores: Range 0-27. A score of 10 or above indicates moderate-to-severe depression and typically warrants treatment. Item 9 screens for suicidal ideation directly; any endorsement (score ≥ 1) requires immediate safety assessment regardless of total score.

GAD-7 scores: Range 0-21. A score of 10 or above indicates moderate anxiety. Scoring 15+ suggests severe anxiety and may warrant pharmacological or intensive psychological intervention.

K10 scores: Range 10-50. Scores 10-15 = low distress; 16-21 = mild; 22-29 = moderate; 30-50 = severe. Used across Australia as a standard outcome measure in mental health services.

HADS scores: Each subscale (anxiety and depression) ranges 0-21. Cutoffs: 0-7 = normal, 8-10 = borderline, 11-21 = clinical range. Useful in medical settings where pure psychiatric diagnosis is not the goal.

DASS-21 scores: Three 7-item subscales cover depression, anxiety, and stress, each item scored 0-3. Multiply each subscale total by 2 to align with the full DASS-42 severity bands published in the UNSW DASS scoring guide.

• Depression: normal 0-9, mild 10-13, moderate 14-20, severe 21-27, extremely severe 28+
• Anxiety: normal 0-7, mild 8-9, moderate 10-14, severe 15-19, extremely severe 20+
• Stress: normal 0-14, mild 15-18, moderate 19-25, severe 26-33, extremely severe 34+

When to refer for professional mental health evaluation

Screening results inform referral decisions. A positive screen does not mandate referral, but specific clinical situations demand urgent evaluation or specialist care.

Refer immediately if any of the following apply:

• Suicidal or homicidal ideation is endorsed (any score on PHQ-9 item 9, or direct disclosure during a clinical interview)
• Acute functional impairment: unable to work, attend school, or care for self
• Psychotic symptoms, such as hallucinations or delusions
• Symptoms following trauma or a major life stressor
• Substance use paired with depression or anxiety, particularly before starting opioid therapy, where the opioid risk tool adds a complementary risk score

Consider referral if any of the following apply:

• The score is in the clinical range, but the patient has no prior treatment history
• Treatment has been ongoing without improvement for 6-8 weeks
• The patient is pregnant, postpartum, or breastfeeding, raising medication safety concerns
• Comorbid medical conditions complicate mental health, such as diabetes with depression
• The patient expresses strong interest in specialist care

Patient engagement in mental health improves when clinicians frame referral as a collaborative step rather than a failure of current care. Framing a higher score as a signal that the case needs specialist expertise, rather than a sign the patient has failed, keeps the relationship on track.

Storing and protecting anxiety and depression test data

Completed screening questionnaires are protected health information (PHI). Any digital or paper storage must comply with HIPAA-compliant screening data storage requirements.

Best practices for protecting anxiety and depression test data include:

1. Scan paper forms into encrypted digital records and destroy originals per retention policy.
2. Use digital screening questionnaires administered directly in your practice management system, which auto-timestamps and logs access.
3. Ensure automatic logoff, role-based access controls, and audit trails.
4. Never email test results or scores to external addresses without patient consent and encrypted transmission.
5. Train all staff on PHI handling.

Conclusion

An anxiety and depression test provides a structured, time-efficient baseline of symptom severity. It standardizes communication between clinician and patient, tracks longitudinal change, and flags cases needing urgent intervention. However, the test alone never produces a diagnosis. Clinical judgment, informed consent, safety assessment, and a thorough diagnostic interview remain essential.

Practices that integrate evidence-based screening into intake workflows report faster diagnosis, improved treatment selection, and better patient outcomes. Therapy practice management software with built-in forms and scoring automation removes administrative burden and ensures consistency across sessions.

Book a demo with Pabau to see how digital mental health intake forms and automated scoring streamline screening workflows in your practice.

Frequently asked questions